Zagotenemab

DB16674InvestigationalProtein Based Therapies

Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).

Mechanism: Pharmacologically active on Microtubule-associated protein tau
Curator reviewed
Code names: LY-3303560

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zagotenemab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.